Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0FHWVC |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | AXL02 |
|||||
| Organization | Fudan University School of Pharmacy.; Shanghai Institute of Materia Medica, Chinese Academy of Sciences. |
|||||
| Synonyms |
AXL02
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Tyrosine-protein kinase receptor UFO (AXL) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
AXL02-MMAE [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 0.1 nM | High AXL expression (AXL +++) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Lung large cell carcinoma | LCLC-103H cells | CVCL_1375 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 0.1 nM | High AXL expression (AXL +++) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | Hs578T cells | CVCL_0332 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 0.1 nM | High AXL expression (AXL +++) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Lung adenocarcinoma | PC9 cells | CVCL_B260 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 0.1 nM | High AXL expression (AXL +++) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 0.1 nM | High AXL expression (AXL +++) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 0.1 nM | High AXL expression (AXL +++) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Lung squamous cell carcinoma | Calu-1 cells | CVCL_0608 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 100 nM | Low AXL expression (AXL+) | ||
| Method Description |
Tumor cells were plated in 96-well plates at predetermined density, treated with AXL02-MMAE or hIgG1-MMAE for 5-8 days to ensure that the doubling of the cells is sufficient. Then MTS reagent (Promega, Cat#G111A, WI, USA) solution was added with replacing fresh medium, and cells were incubated for an appropriate time to ensure that the maximum net absorbance was between 0.5 and 1 at 490 nm.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-453 cells | CVCL_0418 | ||
References